When top corporate officials began cold-calling federal agencies during the March 2020 pandemic lockdown to see how Eastman Kodak Co., which manufactures chemicals, could help reduce expected shortages of essential medicines, it was a changed company from the consumer photography giant that had come to serve as a lesson in what can go wrong when you are overconfident and slow to adapt.
There was a hunger to find the next new thing for an iconic business that had fallen on hard times, and a belief that helping to revitalize domestic pharmaceutical manufacturing when
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?